TNAX Biopharma Corporation
Latest round
- Series A
Last raised
- Nov 2018
Total raised
- $4.4M
Investors
- 3
About TNAX Biopharma Corporation
Founded in 2018, TNAX Biopharma Corporation is based in Tsukuba, Japan, and specializes in developing antibody therapeutics.TNAX Biopharma Corporation specializes in the development and commercialization of innovative antibody therapeutics aimed at addressing significant unmet medical needs in patients suffering from intractable diseases. The company's core product offerings are centered around novel antibodies targeting conditions such as cardiac surgery-associated acute kidney injury (CSA-AKI) and acute ischemic stroke (AIS). These therapeutics are designed to mitigate the serious complications arising from procedures like coronary artery bypass grafting (CABG) and to address the ischemia-reperfusion injury associated with recanalization therapy for AIS. TNAX Biopharma collaborates closely with the University of Tsukuba, leveraging exclusive intellectual property rights for their therapeutic development.TNAX Biopharma's revenue generation strategy includes partnerships with healthcare institutions and potential pharmaceutical collaborators. The company engages in B2B transactions, aiming to supply hospitals and healthcare providers with its therapeutic products. These partnerships may involve joint ventures or licensing agreements, allowing for the distribution of their innovative antibody therapeutics. The transaction structure is designed to facilitate bulk procurement by healthcare providers, which can include subscription-based access to new therapies as they become available. The firm is focusing on launching new therapeutic products aimed at addressing CSA-AKI and AIS. Future expansion plans include targeting healthcare markets in the United States and Europe by 2025, ensuring that their antibody therapeutics reach a broader patient population.
Who invested in TNAX Biopharma Corporation
3 investors across 1 round
See all investors in TNAX Biopharma Corporation
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 30, 2018
Amount
$4.4M
Investors
Questions about TNAX Biopharma Corporation
Who invested in TNAX Biopharma Corporation?
TNAX Biopharma Corporation has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TNAX Biopharma Corporation raised?
TNAX Biopharma Corporation has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TNAX Biopharma Corporation last raise money?
TNAX Biopharma Corporation's most recent round on record is a Series A, in Nov 2018.
What does TNAX Biopharma Corporation do?
Founded in 2018, TNAX Biopharma Corporation is based in Tsukuba, Japan, and specializes in developing antibody therapeutics.
Where is TNAX Biopharma Corporation headquartered?
TNAX Biopharma Corporation is headquartered in Tsukuba, Japan.
Which VCs invest in companies like TNAX Biopharma Corporation?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at TNAX Biopharma Corporation's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like TNAX Biopharma Corporation? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.